261 related articles for article (PubMed ID: 31804034)
1. [Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
Stebler-Fontaine L; Rossel A; Marti C; Righini M; Robert-Ebadi H
Rev Med Suisse; 2019 Dec; 15(674):2232-2235. PubMed ID: 31804034
[TBL] [Abstract][Full Text] [Related]
2. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Abdel-Razeq H; Finianos A; Taher AT
Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of cancer-associated venous thromboembolism].
Di Nisio M
G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
Rojas-Hernandez CM; Oo TH
Drugs; 2019 Apr; 79(6):621-631. PubMed ID: 30905033
[TBL] [Abstract][Full Text] [Related]
7. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Khorana AA; Noble S; Lee AYY; Soff G; Meyer G; O'Connell C; Carrier M
J Thromb Haemost; 2018 Sep; 16(9):1891-1894. PubMed ID: 30027649
[No Abstract] [Full Text] [Related]
8. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
[TBL] [Abstract][Full Text] [Related]
9. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy.
Finks SW; Trujillo TC; Dobesh PP
Ann Pharmacother; 2016 Jun; 50(6):486-501. PubMed ID: 26917821
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants.
Carrier M; Soff G; Le Gal G
Cancer Treat Res; 2019; 179():103-115. PubMed ID: 31317483
[TBL] [Abstract][Full Text] [Related]
11. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Riaz IB; Fuentes HE; Naqvi SAA; He H; Sipra QR; Tafur AJ; Padranos L; Wysokinski WE; Marshall AL; Vandvik PO; Montori V; Bryce AH; Liu H; Badgett RG; Murad MH; McBane RD
Mayo Clin Proc; 2022 Feb; 97(2):308-324. PubMed ID: 34172290
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
Weitz JI; Jaffer IH
Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
[TBL] [Abstract][Full Text] [Related]
14. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
Imberti D; Mastroiacovo D
Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated thrombosis: investigating the role of new oral anticoagulants.
Franchini M; Bonfanti C; Lippi G
Thromb Res; 2015 May; 135(5):777-81. PubMed ID: 25743884
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies.
Choe HK; De Sancho MT; Kim SS; Dai T; Shah MA
Blood Coagul Fibrinolysis; 2018 Mar; 29(2):227-230. PubMed ID: 29389673
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
[TBL] [Abstract][Full Text] [Related]
18. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
